Kornimate/medical-research-clean huggingface dataset:
the use of fractionated exhaled nitric oxide in the diagnosis and assessment of disease activity of eosinophilic esophagitis (validation phase)

Conditions: Eosinophilic Esophagitis

Summary: the purpose of this study is to evaluate the relationship between fractionated exhaled nitric oxide, peripheral eosinophils, and plasma citrulline and ß-alanine in patients with eosinophilic esophagitis (eoe) compared to those without eoe. the hypothesis is that a combination of elevated fractional exhaled nitric oxide, increased peripheral eosinophils, and elevated plasma citrulline and ß-alanine is associated with active eoe.


Eligibility criteria:
inclusion criteria: * pediatric patient, ages 5-18 years old, who will undergo esophagogastroduodenoscopy with biopsies at children's memorial hermann hospital, as part of the standard of care in the evaluation of eoe * signed informed consent by a parent or legal guardian * signed assent form by the child/adolescent subjects 7-18 years of age exclusion criteria: * past medical history of active asthma, active allergic rhinitis, inflammatory bowel disease (ibd), parasitic infection, hay fever and any exposure to smoking (including secondhand smoke) because these disorders are known to affect the feno levels * active respiratory tract infections at the time of feno evaluation because this can affect the result of the feno as well * asthma questionnaire and/or spirometry test consistent with asthma
study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of amg 181.

Conditions: Ulcerative Colitis; Crohn's Disease

Summary: to assess the safety and tolerability of multiple subcutaneous doses of amg 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active crohn's disease.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 18 and 34 kg/m2 * normal physical and neurological examination, clinical laboratory values and ecg * ulcerative colitis disease activity index (ucdai, aka mayo score) score of 4 to 10 (inclusive), with a minimum sigmoidoscopy score of 1; (for subjects with ulcerative colitis) * crohn's disease activity index (cdai) score of \>150 and \< 450 at screening (for subjects with crohn's disease) * additional inclusion criteria apply exclusion criteria: * history or evidence of a clinically significant disorder (including psychiatric), condition or disease that would pose a risk to subject safety or interfere with the study evaluations, procedures or completion * history of malignancy of any type, other than in situ cervical cancer or surgically excised non-melanomatous skin cancers within the past 5 years * underlying condition(s) that predisposes the subject to infections * disease limited to the rectum, i.e. within 10 cm of the anal verge (for subjects with ulcerative colitis) * evidence of severe disease (as evidenced by an hb concentration less or equal to 10g/dl; toxic megacolon, or an ucdai score greater than 10) (for subjects with ulcerative colitis) * subject has short bowel syndrome (for subjects with crohn's disease) * presence of an ostomy (for subjects with crohn's disease) * presence of a fistula (for subjects with crohn's disease) * additional exclusion criteria apply
pharmacist use of ecg to inform drug therapy decisions for patients receiving qt prolonging medications

Conditions: Torsades de Pointe Caused by Drug (Disorder); Torsades de Pointes; Qt Interval, Variation in

Summary: torsade de pointes (tdp) is a cardiac arrhythmia associated with qt interval prolongation which may lead to cardiac arrest. prescription medications which cause qt interval prolongation are commonly used in daily practice. to lessen risk of tdp, pharmacists work to minimize combinations of qt interval prolonging drugs. if community pharmacists had real-time information about a patient's qt interval duration, this would have the direct ability to inform their decision making about which patients may be at highest risk of tdp and who may need heightened avoidance of qt prolonging drugs. this project will provide 3 community pharmacies with mobile ecg devices to easily determine qt intervals among patients who have a prescription profile alert for qt interval prolongation. study outcomes will include: frequency of qt interval prolongation, changes in drug therapy related to qt interval determination, and patient and pharmacist satisfaction with having pharmacist assessment of qt interval.


Eligibility criteria:
inclusion criteria: 1. male or female at least 18 years of age. 2. subject is receiving a prescription medication for which there is a "qt/qtc interval prolongation" alert observed on the dispensing pharmacy prescription software. 3. english speaking exclusion criteria: 1. patients with implantable pacemakers or automatic implantable cardioverter defibrillators 2. mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. 3. patient has known atrial or ventricular arrhythmia
observational study on levemir® in obese diabetic patients

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this study is conducted in europe. the aim of this observational study is to investigate the effect of switch from other basal insulin treatments to levemir® on body weight in obese diabetic patients. a local extension will be conducted in slovenia in order to reach the planned 400 patients for the sub-analysis of slovenian patients. included in the study is a retrospective part to evaluate the weight progress since initiation of insulin treatment of another basal insulin and/or oral antidiabetic drugs (oad) and/or bolus insulin therapy. retrospective data will be collected at baseline and at approximately 6 and 12 months before starting insulin detemir therapy.


Eligibility criteria:
inclusion criteria: * diabetes mellitus (type 1 or type 2) * bmi greater than 27 kg/m\^2, or more than 3 kg weight increase since start of insulin therapy exclusion criteria: * subjects currently being treated with insulin detemir * subjects who were previously enrolled in this study; * subjects with a hypersensitivity to insulin detemir or to any of the excipients. * women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months female patients will be reminded to use adequate contraceptive during the study, where is relevant.
trial comparing capecitabine plus oxaliplatin (xelox) and capecitabine (x) as first-line chemotherapy in elderly patients with advanced gastric cancer

Conditions: Gastric Cancer

Summary: the objective of the trial is to compare overall survival between capecitabine plus oxaliplatin (xelox) and capecitabine (x) as first-line chemotherapy in elderly patients with advanced gastric cancer.


Eligibility criteria:
inclusion criteria: 1. age ≥ 70 2. histologically or cytologically confirmed adenocarcinoma of the gastric 3. advanced ,metastatic/recurrence gastric cancer 4. ecog performance status of 0 to 2 5. life expectancy≥3months 6. no history of any systemic anti-cancer chemotherapy (prior adjuvant chemoradiation or chemotherapy is allowed if the last date of drug administration is \> 6months from the study entry date) 7. no history of radiation therapy about target lesion. (prior radiotherapy is permitted if it was not administered to target lesions selected for this study, unless progression of the selected target lesions within the radiation portal is documented, and provided it has been completed at least 4 weeks before randomization. 8. adequate marrow functions (anc ≥ 1,500/ul, plt ≥100,000/ul) 9. adequate renal functions (creatinine ≤1.5mg/dl or ccr ≥ 50ml/min) 10. adequate hepatic functions ( bilirubin ≤ 2.0mg/dl, sgot/sgpt \< normal x 3) 11. provision of a signed written informed consent exclusion criteria: 1. history of any medical or psychiatric condition 2. active infections 3. peripheral neuropathy with symptom(nci-ctcae ver. 3.0 \>=grade 1 ) 4. symptomatic brain metastases 5. double primary cancer (physician at the discretion of the other cancer cured the purpose of early cancer cases can be registered) 6. history of other malignancy except: adequately treated non-melanomatous skin cancer or cervical carcinoma in situ 7. known hypersensitivity to fluoropyrimidines/platinum 8. clinical significant cardiovascular disease (myocardial infarction, symptomatic coronary artery disease, congestive heart failure, severe arrhythmias) 9. required immunosuppressive therapy(transplant patients, severe autoimmune disease)
evaluation of covid-19 fear, anxiety and their effects in physiotherapy technician students

Conditions: Covid19; Anxiety and Fear

Summary: 80 participants studying in the physiotherapy technician department were included in this cross-sectional study. participants' age, gender, year of being a student, the people they live with, the precautions they take regarding covid-19, whether there is a history of covid-19 in them or their immediate surroundings, and whether they have covid-19 transmission and / or contagion fears during their vocational training, whether there are fears of achieving professional goals and competence because of covid-19 and / or its consequences were recorded. afterwards, the participants were asked to answer the questions on the coronavirus anxiety scale, the fear of covid-19 scale and the cognitive and behavioral avoidance subscales of the avoidance attitudes from covid-19 scale.


Eligibility criteria:
inclusion criteria: 1. being between the ages of 18-65 2. being a physiotherapy technician student exclusion criteria: 1. being under the age of 18, over the age of 65
cast immobilization versus percutaneous pinning for fracture of radius in an elderly patient

Conditions: Closed Fracture of Lower End of Radius

Summary: distal radius fractures, particularly in elderly individuals, are a common problem associated with increasing age and hormonal changes. the choice of treatment, such as cast immobilization or percutaneous pinning, plays a crucial role in achieving optimal functional outcomes and facilitating a return to normal activities. this study aimed to compare the radiological and clinical outcomes of cast immobilization and percutaneous pinning in elderly patients with distal radius fractures.

background: distal radius fractures, particularly in elderly individuals, are a common problem associated with increasing age and hormonal changes. the choice of treatment, such as cast immobilization or percutaneous pinning, plays a crucial role in achieving optimal functional outcomes and facilitating a return to normal activities. this study aimed to compare the radiological and clinical outcomes of cast immobilization and percutaneous pinning in elderly patients with distal radius fractures. methods: this prospective randomized controlled trial enrolled participants aged over 60 years with ao23-a2 or ao23-a3 distal radius fractures and no contraindications for local anesthesia. the participants were randomly assigned to either the cast immobilization or percutaneous pinning group. follow-up was conducted for 3 months, during which radiological outcomes and clinical outcomes were assessed. radiological parameters included radial angulation, while clinical outcomes were evaluated using the disability of arm, shoulder, and hand (dash) score, range of motion, and grip strength. additionally, data on complications and pain levels measured using the visual analog scale (vas) were collected for the percutaneous pinning group under local anesthesia.

Eligibility criteria:
inclusion criteria: * aged \>60 years * primary distal end radius fracture type ao23-a2 or ao23-a3 exclusion criteria: * multiple trauma * onset \> 2 weeks * systemic diseases such as ra * steroid user * contraindication for la
effect of physical activity on nafld

Conditions: NAFLD

Summary: it has been demonstrated the essential role of physical activity in the prevention of overweight and obesity. nevertheless, the effect of a program of physical activity on the maintenance of body weight in subjects who have previously followed a dietary intervention is still unknown. the aim of this study was to investigate this topic by evaluating the effect of two different programs of physical activity on subjects who have followed a dietary intervention but presented again nafld a year after the treatment.

subjects who were previously enrolled in the trial nutriep and who still have nafld a year after the end of the study, were invited to participate in a program of physical activity to assess the effect of endurance and resistance training on weight and nafld score. participants (100 subjects) were randomized and divided into two groups: the first followed a program of endurance activity consisting in a 30 minute walk, 5 times/week; the second followed a program combining the just described aerobic exercise with a resistance training based on 30 minute of musculation involving all the bigger muscles, 3 times/week. the trial lasted six months and subjects underwent liver ultrasonography (to assess nafld score), indirect calorimetry, bioimpedenziometry, the measurement of anthropometric variables (body height and weight) and biological parameters (glucose, insulin, cholesterol, hdl cholesterol, triglycerides, got, gpt and ggt) at the baseline and at the third and the sixth month. the aim of the study was to estimate the effect of the two different programs of physical activity on nafld score. secondary end-points included: the effect on basal metabolism, the modification of fat mass (fm), lean mass (lm) and muscle mass (mm) and on several biological markers associated with nafld.

Eligibility criteria:
inclusion criteria: * moderate or severe nafld * enrolled in the previous trial called nutriep exclusion criteria: * not enrolled in the previous trial called nutriep

Keywords: diet physical activity nafld
a study of ac682 for the treatment of locally advanced or metastatic er+ breast cancer

Conditions: Breast Cancer

Summary: this clinical trial is evaluating a drug called ac682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (er+/her2-) locally advanced or metastatic breast cancer. the main goals of this study are to: * identify the recommended dose of ac682 that can be given safely to participants * to evaluate the side effects of ac682 * to evaluate pharmacokinetics of ac682 * to evaluate the effectiveness of ac682

this is a phase i, first in human, open-label dose-escalation study of ac682, an orally available estrogen receptor degrader, given as a single agent.

Eligibility criteria:
inclusion criteria: * signed written informed consent form (icf) * patients must be ≥18 years-of-age at the time of signing of the icf * female patients must be postmenopausal * eastern cooperative oncology group (ecog) performance status score of 0 or 1 * histologically and/or cytologically confirmed advanced estrogen receptor positive (er+) human epidermal growth factor 2 negative (her2-) breast cancer * patients with life expectancy ≥3 months * patients who have adequate organ functions at baseline * at least 1 measurable lesion that meets the definition in response evaluation criteria in solid tumors (recist) version 1.1 or at least 1 non-target lesion is required. exclusion criteria: * treatment with any of the following: systemic anti-cancer chemotherapy, biologic, or hormonal agent from a previous treatment regimen or clinical study within 4 weeks prior to the first dose of ac682; systemic small molecules from a previous treatment regimen or clinical study within 14 days or 5 half-lives (whichever is longer) prior to the first dose of ac682 (at least 10 days must have elapsed between the last dose of such agent and the first dose of study drug) * radiation therapy such as wide-field radiotherapy administered ≤28 days of first dose of ac682 * major surgery (excluding placement of vascular access) within 4 weeks of first dose of ac682 * known symptomatic brain metastases requiring the use of steroids * any condition that impairs a patient's ability to swallow whole pills. impairment of gastrointestinal function (gi) or gi disease or other condition at baseline that will interfere significantly with the absorption, distribution, or metabolism of ac682. * use of prophylactic growth factors and blood transfusions ≤14 days prior to the first dose of ac682 and during dose limiting toxicity observation period

Keywords: estrogen receptor positive er positive er+ human epidermal growth factor receptor 2 negative her2 negative her2- ac682 breast cancer phase i
proteomic profiling in diagnosing ovarian cancer in patients who are undergoing surgery for an abnormal pelvic mass

Conditions: Fallopian Tube Cancer; Ovarian Cancer

Summary: rationale: finding specific proteins in the blood may help doctors tell whether a patient has ovarian cancer. purpose: this clinical trial is studying how well proteomic profiling works in diagnosing ovarian cancer in patients who are undergoing surgery for an abnormal pelvic mass.

objectives: primary * generate and validate a serum proteomic profile that can predict the presence of invasive ovarian epithelial cancer using preoperative serum specimens obtained from patients undergoing surgical evaluation for an abnormal pelvic mass. secondary * generate a proteomic profile that can distinguish early- from late-stage invasive ovarian epithelial cancer using preoperative serum specimens from patients who are subsequently diagnosed with invasive ovarian epithelial cancer. tertiary * determine whether serum proteomic profiling can predict the presence of postoperative residual disease in these patients. * determine whether serum proteomic profiling can predict prognosis in these patients. outline: this is a pilot, two-part, multicenter study. * part a: within 3 weeks prior to surgical evaluation, patients undergo collection of serum specimen for proteomic profiling using surface-enhanced or matrix-associated laser desorption ionization spectrometry-time of flight detection (seldi/maldi-tof). patients then undergo surgical evaluation (i.e., biopsy and/or resection) of the pelvic mass. patients who are diagnosed with invasive ovarian epithelial adenocarcinoma or papillary serous fallopian tube carcinoma (no low malignant potential tumors) and are without postoperative infection proceed to part b of the study. * part b: patients undergo collection of postoperative serum specimen for proteomic profiling using seldi/maldi-tof within 3-8 weeks after surgery, before starting chemotherapy, and at end of chemotherapy. after completion of study procedures, patients are followed periodically for up to 10 years. projected accrual: a total of 2,000 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * abnormal pelvic mass by physical examination or imaging test * undiagnosed * planning to undergo surgical evaluation within the next 3 weeks patient characteristics: performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified other * negative pregnancy test prior concurrent therapy: surgery * see disease characteristics

Keywords: stage i ovarian epithelial cancer stage ii ovarian epithelial cancer stage iii ovarian epithelial cancer stage iv ovarian epithelial cancer fallopian tube cancer ovarian clear cell cystadenocarcinoma ovarian endometrioid adenocarcinoma ovarian mucinous cystadenocarcinoma ovarian serous cystadenocarcinoma ovarian undifferentiated adenocarcinoma
effects of high-frequency deep diathermy on heart rate variability in women with primary dysmenorrhea

Conditions: Primary Dysmenorrhea; Dysmucorrhea

Summary: superficial heat therapy is mainly used to relieve menstrual pain, but it does not penetrate deeper than the skin tissue. in order to penetrate deep into the deep layers and promote tissue relaxation, deep heat therapy can be effective. the treatment time for deep heat treatment is controversial, and there is no study on deep heat treatment using radio frequency for dysmenorrhea. therefore, in this study, by applying radiofrequency waves at different times to the lower abdomen for patients with primary dysmenorrhea, the pain and changes in the autonomic nervous system were compared with thermotherapy to suggest appropriate therapeutic interventions.


Eligibility criteria:
inclusion criteria: * women between the ages of 18-50 * regular menstrual cycle (24-32 days) * those who have had symptoms of primary dysmenorrhea for at least 1 year * those who have lower back pain symptoms related to menstrual pain of 5 or higher on the visual analysis scale (vas) * the body mass index is between 20-30 exclusion criteria: * pelvic inflammatory disease * uterine fibroids, polycystic ovary syndrome. those with gynecological findings such as endometriosis * those who have used an intrauterine contraceptive device * those who took birth control pills or nonsteroidal anti-inflammatory drugs at the time of the experiment
concentrated growth factor versus platelet rich fibrin in revitalization of necrotic young permanent incisors

Conditions: Necrotic Pulp

Summary: regenerative endodontic procedures (reps) are the most recent proposal to manage immature permanent teeth with necrotic pulps. so in this study, the investigator will evaluate the clinical and radiographical revitalization success in necrotic young permanent anterior teeth of participants by using concentrated growth factor versus platelet-rich fibrin

has been entered

Eligibility criteria:
inclusion criteria: * healthy patients with immature permanent incisors * presence of clinical signs and symptoms of necrosis or chronic apical periodontitis. the chronic apical periodontitis signs and symptoms include little discomfort with intermittent episodes of pus discharge through the sinus tract. exclusion criteria 1. abnormal tooth mobility. * positive history of allergic reaction, systemic diseases, severe emotional or behavioral problems. * unrestorable teeth * abnormal tooth mobility * children with systemic, severe behavioral, or emotional problems
efficacy of sasi bypass in super obese patients

Conditions: Morbid Obesity

Summary: although previous studies investigated weight loss and improvement in comorbidities after sasi bypass, patients included in these studies had a bmi less than 50 kg/m2. therefore, the aim of the present study was to investigate the outcome of sasi bypass in patients with super obesity to assess the success of this novel bariatric procedure in this challenging group of patients in regards weight loss and improvement in associated comorbid conditions at 12 months postoperatively.


Eligibility criteria:
inclusion criteria: * patients included to the present study were adult patients of both genders aging between 18 and 65 years with primary morbid obesity with bmi ≥50 kg/m2 with or without obesity-associated comorbidities such as hypertension, diabetes mellitus (dm), dyslipidemias, and gastroesophageal reflux disease (gerd). exclusion criteria: * pregnant women. * patients unfit for general anasthesia (asa 4, 5) * endocrine or psychiatric disorders. * history of previous upper abdmominal laparotomy. * alcoholic addiction * liver cirrhosis * coagulopathy